Stephenson Harwood LLP has advised UCB Ventures, BGF and 4Bio Capital, who led the over-subscribed Series A funding round of $25million in ViaNautis Bio.
ViaNautis, formerly known as SomaServe, has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.
The raise was led by UCB Ventures, BGF and 4Bio Capital, and additional participation was provided by the Cystic Fibrosis Foundation, Eli Lilly and Company, as well as existing investors including Origin Capital, Meltwind and O2H. The proceeds from the round will be used to fuel the rapid development of products using the polyNaut® platform, expand the scientific and management teams and establish industry-leading laboratory facilities. ViaNautis' proprietary drug delivery platform is designed to deliver genetic therapeutic payloads to the specific site of action.
The Stephenson Harwood team comprised of corporate partner Anthony Clare and corporate associates Michelle Gomes and Yuki Yue, with further assistance provided by IP partner Naomi Leach and associate Ainsleigh Stone.